Neothetics (NEOT) Updates Outlook on Release of Top-Line Data for Two LIPO-202 Phase 3s

Neothetics (NASDAQ: NEOT) tightened its guidance regarding the timing of release of top-line data for its two pivotal U.S. Phase 3 trials titled AbCONTOUR1 and AbCONTOUR2 of LIPO-202 to mid-December. LIPO-202 is the first non-invasive injectable drug candidate for reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.

You May Also Be Interested In

• Safe & Green (SGBX) Provides Update on Audit and Planned 10-K Filing
• Procter & Gamble (PG) revenue falls short of expectations, raises full-year earnings guidance
• RumbleOn Inc. (RMBL) Appoints Michael Quartieri to its Board